RP-HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-02. Numbers and descriptions here follow the published literature rather than marketing material.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
=== Misinformation === Naloxone has been subject to much inaccurate media reporting and many urban legends about it have become prevalent. One such myth is that naloxone makes the recipient violent. Another is that events called "Lazarus parties" have taken place, in which people reportedly took fatal overdoses in anticipation of being treated with naloxone; in reality this was a fiction spread by the police. Yet another is the claim that people have indulged in "yo-yoing", whereby they would take naloxone and opioids simultaneously to enjoy an extreme "high" and subsequent revival; the idea is scientifically nonsensical.
As part of Biden's Build Back Better agenda, in late March 2021, he proposed the American Jobs Plan, a $2 trillion package addressing issues including transport infrastructure, utilities infrastructure, broadband infrastructure, housing, schools, manufacturing, research and workforce development. After months of negotiations among Biden and lawmakers, in August 2021 the Senate passed a $1 trillion bipartisan infrastructure bill called the Infrastructure Investment and Jobs Act, while the House, also in a bipartisan manner, approved that bill in early November 2021, covering infrastructure related to transport, utilities, and broadband. Biden signed the bill into law in mid-November 2021. The other core part of the Build Back Better agenda was the Build Back Better Act, a $3.5 trillion social spending bill that expands the social safety net and includes major provisions on climate change. Democrats attempted to pass it on a party-line vote through budget reconciliation, but struggled to win the support of Senator Joe Manchin, even as the price was lowered to $2.2 trillion. After Manchin rejected the bill, it was comprehensively reworked into the Inflation Reduction Act of 2022, covering deficit reduction, climate change, healthcare, and tax reform. The Inflation Reduction Act of 2022 was introduced by Manchin and Senator Chuck Schumer.
Neopentalenolactone D synthase (EC 1.14.13.171, ptlE (gene)) is an enzyme with systematic name 1-deoxy-11-oxopentalenate,NADH:oxygen oxidoreductase (neopentalenolactone-D forming). This enzyme catalyses the following chemical reaction
Sources: en.wikipedia.org
=== Independent Grand Lodge of Colon === At the insistence of Albert Pike (after he had been allowed to return from exile to the United States), in 1867, the Grand Lodge of Colon under the leadership of Grand Master Andrés Puente, established its own constitution. Even though they recognized the sovereignty of the Supreme Council, their new constitution established that the Grand Lodge of Colon held the exclusive authority to enact its own bylaws, issue charters, and regulate its own Lodges. Albert Pike gave his staunch support and approval in the new autonomy of the Grand Lodge. The Supreme Council of the Scottish Rite in Cuba, however, outright refused to recognize any independent authority of the Grand Lodge of Colon. They dissolved the Grand Lodge and assumed all of its orders. On September 20, 1867, the Grand Lodge of Colon agreed to suspend their constitution until a joint meeting of the Supreme Council and the Grand Lodge could occur, where the parties were scheduled to discuss the situation. That meeting was scheduled to happen on November 25, 1868. That meeting never took place, due to the outbreak of the Ten Years' War.
=== Kidney transplant === SIUT is performing deceased organ donation since two decades as one person loses his fight to live every 3 minutes due to end stage organ failure in the country. First renal transplant was performed at SIUT Chablani Medical Center, Sukkur on Sunday 28 April 2019.
== Adverse effects == The drug label (in some jurisdictions) has warnings with regard to the risk of respiratory depression, anticholinergic toxicity and opioid overdose, the risk of dehydration and electrolyte imbalance that people with severe diarrhea always run, and toxic megacolon in people with ulcerative colitis. Other adverse effects include numbness in the hands and feet, euphoria, depression, lethargy, confusion, drowsiness, dizziness, restlessness, headache, hallucinations, edema, hives, swollen gums, itchiness, vomiting, nausea, loss of appetite, and stomach pain.
Sources: en.wikipedia.org
==== Impact on the environment ==== Post incineration process, toxic ash residue is produced and is often disposed at landfills. These landfills are not protected by any barrier and the residue has the potential of reaching underground water that is often exposed to human use. The combustion of plastic material releases toxic gases that escapes and joins breathable air. Human and animal exposure to such gases can cause long term breathing and health issues. The rotation of toxic air does not only impact human well-being, but also of animals and plants. Air pollution caused by the incinerators depletes the ozone layer, causes crop and forest damage, and increases the effects of climate change. Constant exposure to such toxins and chemicals in the air could be deemed detrimental to trees and plants and could eventually lead to extinction of certain plants in specific areas. Pollution and chemical leaks also affect the fruits of trees and would cause them to be poisonous and therefore inedible.
Since the exciton samples many potential analyte binding sites during its excited state lifetime, the probability that the exciton will sample an occupied ‘receptor’ site and be quenched is greatly increased."
Commission A2: Liquefaction and Separation of Gases The work of "Commission A2: Liquefaction and Separation of Gases" reflects worldwide activities in the domain of separation of gases and liquefaction. Apart from the personal involvement of Commission members in various projects, the commission is present at conferences, workshops and seminars: LNG International Exhibition and Conference, GASTECH, Cryogenics, Cryogen Expos, European Cryogenic Course and others. The commission is close to academia, industry and end users of separated and liquefied gases. Commission members work closely with Commission A1 Cryophysics, Cryoengineering and Commission C1 Cryobiology, Cryomedicine and Health Products.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.